Grifols (GIKLY) Change in Receivables (2010 - 2020)
Grifols (GIKLY) reported Change in Receivables of $1.5 million for Q1 2020, up 100.9% on a YoY basis from $738505.3 in Q2 2019, and up 109.81% quarter-over-quarter from -$15.1 million in Q4 2019.
Grifols (GIKLY) Change in Receivables (2010 - 2020) Analysis & Trends
Grifols has reported Change in Receivables for 10 years, with the latest figure at $1.5 million in Q1 2020.
- For the quarter ending Q1 2020, Change in Receivables rose 100.9% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2020 stood at -$160.7 million (up 27.66% YoY), and the FY2025 full-year result was -$37.2 million, up 17.0% from the prior year.
- Change in Receivables for Q1 2020 stood at $1.5 million, up from -$15.1 million in the prior quarter.
- The five-year high for Change in Receivables was $81.5 million in Q4 2017, with the low at -$163.9 million in Q1 2019.
- Historically, Change in Receivables has averaged -$4.0 million across 5 years, with a median of $3.5 million in 2016.
- Annual changes were most pronounced in 2017 — Change in Receivables soared 2206.94% — and 2019, when it plunged 1195.73%.
- Grifols' Change in Receivables stood at $3.5 million in 2016, then soared by 2206.94% to $81.5 million in 2017, then plunged by 79.25% to $16.9 million in 2018, then sank by 189.44% to -$15.1 million in 2019, then surged by 109.81% to $1.5 million in 2020.
- The last three Change in Receivables figures came in at $1.5 million (Q1 2020), -$15.1 million (Q4 2019), and -$163.9 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.48 Mn |
| Mar 31, 2020 | 1.48 Mn |
| Dec 31, 2019 | -15.12 Mn |
| Dec 31, 2019 | -15.12 Mn |
| Mar 31, 2019 | -163.95 Mn |
| Mar 31, 2019 | -163.95 Mn |
| Dec 31, 2018 | 16.91 Mn |
| Dec 31, 2018 | 16.91 Mn |
| Jun 30, 2018 | -90.04 Mn |
| Jun 30, 2018 | -90.04 Mn |
| Mar 31, 2018 | 14.96 Mn |
| Mar 31, 2018 | 14.96 Mn |
| Dec 31, 2017 | 81.48 Mn |
| Dec 31, 2017 | 81.48 Mn |
| Jun 30, 2017 | -19.98 Mn |
| Jun 30, 2017 | -19.98 Mn |
| Mar 31, 2017 | 61.00 Mn |
| Mar 31, 2017 | 61.00 Mn |
| Dec 31, 2016 | 3.53 Mn |
| Dec 31, 2016 | 3.53 Mn |